Expression of organic anion-transporting polypeptide 1A2 and organic cation transporter 6 as a predictor of pathologic response to neoadjuvant chemotherapy in triple negative breast cancer

Breast Cancer Research and Treatment

Volumn 145, Issue 1, 2014, Pages 101-111

  Hashimoto, Yumi ^a   Tatsumi, Shigenobu ^a   Takeda, Risa ^a   Naka, Ayano ^a   Ogane, Naoki ^b   Kameda, Yoichi ^b   Kawachi, Kae ^b   Shimizu, Satoru ^b   Sakai, Mai ^b   Kamoshida, Shingo ^a  

^a KOBE UNIVERSITY   (Japan)

^b KANAGAWA CANCER CENTER   (Japan)

Author keywords

Breast cancer; Immunohistochemistry; Neoadjuvant chemotherapy; Organic anion transporting polypeptide 1A2; Organic cation transporter 6

Indexed keywords

CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIRUBICIN; FLUOROURACIL; HORMONE RECEPTOR; KI 67 ANTIGEN; OCTAMER TRANSCRIPTION FACTOR 6; ORGANIC ANION TRANSPORTING POLYPEPTIDE 1A2; ORGANIC CATION TRANSPORTER 6; PACLITAXEL; TUMOR PROTEIN; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; ORGANIC ANION TRANSPORTER; ORGANIC CATION TRANSPORTER; SLC22A16 PROTEIN, HUMAN; SLCO1A2 PROTEIN, HUMAN; TUMOR MARKER;

ADULT; ARTICLE; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER STAGING; CONTROLLED STUDY; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MULTIPLE CYCLE TREATMENT; NEEDLE BIOPSY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; TREATMENT RESPONSE; TRIPLE NEGATIVE BREAST CANCER; TUMOR VOLUME; ADJUVANT THERAPY; AGED; BIOSYNTHESIS; DRUG RESISTANCE; FEMALE; METABOLISM; MIDDLE AGED; PATHOLOGY; RETROSPECTIVE STUDY; TRIPLE NEGATIVE BREAST NEOPLASMS;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MIDDLE AGED; NEOADJUVANT THERAPY; ORGANIC ANION TRANSPORTERS; ORGANIC CATION TRANSPORT PROTEINS; RETROSPECTIVE STUDIES; TRIPLE NEGATIVE BREAST NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 84900520406     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-014-2913-y     Document Type: Article

References (28)

1. Kaufmann M, von Minckwitz G, Bear HD, Buzdar A, McGale P, Bonnefoi H, Colleoni M, Denkert C, Eiermann W, Jackesz R, Makris A, Miller W, Pierga JY, Semiglazov V, Schneeweiss A, Souchon R, Stearns V, Untch M, Loibl S (2007) Recommendations from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer: new perspectives 2006. Ann Oncol 18:1927-1934
2. Tewari M, Krishnamurthy A, Shukla HS (2008) Predictive markers of response to neoadjuvant chemotherapy in breast cancer. Surg Oncol 17:301-311. doi: 10.1016/j.suronc.2008.03.003
3. Faneyte IF, Schrama JG, Peterse JL, Remijnse PL, Rodenhuis S, van de Vijver MJ (2003) Breast cancer response to neoadjuvant chemotherapy: predictive markers and relation with outcome. Br J Cancer 88:406-412
4. Petit T, Wilt M, Velten M, Millon R, Rodier J-F, Borel C, Mors R, Haegelé P, Eber M, Ghnassia J-P (2004) Comparative value of tumour grade, hormonal receptors, Ki-67, HER-2 and topoisomerase II alpha status as predictive markers in breast cancer patients treated with neoadjuvant anthracycline-based chemotherapy. Eur J Cancer 40:205-211
5. Guarneri V, Broglio K, Kau SW, Cristofanilli M, Buzdar AU, Valero V, Buchholz T, Meric F, Middleton L, Hortobagyi GN, Gonzalez-Angulo AM (2006) Prognostic value of pathologic complete response after primary chemotherapy in relation to hormone receptor status and other factors. J Clin Oncol 24:1037-1044
6. Carey LA, Dees EC, Sawyer L, Gatti L, Moore DT, Collichio F, Ollila DW, Sartor CI, Graham ML, Perou CM (2007) The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes. Clin Cancer Res 13:2329-2334
7. Andre F, Mazouni C, Liedtke C, Kau SW, Frye D, Green M, Gonzalez-Angulo AM, Symmans WF, Hortobagyi GN, Pusztai L (2008) HER2 expression and efficacy of preoperative paclitaxel/FAC chemotherapy in breast cancer. Breast Cancer Res Treat 108:183-190
8. Rody A, Karn T, Gätje R, Ahr A, Solbach C, Kourtis K, Munnes M, Loibl S, Kissler S, Ruckhäberie E, Holtrich U, von Minckwitz G, Kaufmann M (2007) Gene expression profiling of breast cancer patients treated with docetaxel, doxorubicin, and cyclophosphamide within the GEPARTRIO trial: HER-2, but not topoisomerase II alpha and microtubule-associated protein tau, is highly predictive of tumor response. Breast 16:86-93
9. Liedtke C, Mazouni C, Hess KR, André F, Tordai A, Mejia JA, Symmans WF, Gonzalez-Angulo AM, Hennessy B, Green M, Cristofanilli M, Hortobagyi GN, Pusztai L (2008) Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. J Clin Oncol 26:1275-1281. doi: 10.1200/JCO.2007.14.4147
10. Cheang MC, Chia SK, Voduc D, Gao D, Leung S, Snider J (2009) Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer. J Natl Cancer Inst 101:736-750. doi: 10.1093/jnci/djp082
11. Goldhirsh A, Wood WC, Coates AS, Gelber RD, Thürlimann B, Senn HJ (2011) Strategies for subtypes-dealing with the diversity of breast cancer: highlights of the St. Gallen international expert consensus on the primary therapy of early breast cancer 2011. Ann Oncol 22:1736-1747. doi: 10.1093/annonc/mdr304
12. Sissung TM, Baum CE, Kirkland CT, Gao R, Gardner ER, Figg WD (2010) Pharmacogenetics of membrane transporters: an update on current approaches. Mol Biotechnol 44:152-167. doi: 10.1007/s12033-009-9220-6
13. Sprowl JA, Mikkelsen TS, Giovinazzo H, Sparreboom A (2012) Contribution of tumoral and host solute carriers to clinical drug response. Drug Resist Updat 15:5-20. doi: 10.1016/j.drup.2012.01.009
14. Cutler MJ, Choo EF (2011) Overview of SLC22A and SLCO families of drug uptake transporters in the context of cancer treatments. Curr Drug Metab 12:793-807
15. Obaidat A, Roth M, Hagenbuch B (2012) The expression and function of organic anion transporting polypeptides in normal tissues and in cancer. Annu Rev Pharmacol Toxicol 52:135-151. doi: 10.1146/annurev-pharmtox-010510-100556
16. Buxhofer-Ausch V, Secky L, Wlcek K, Svoboda M, Kounnis V, Briasoulis E, Tzakos AG, Jaeger W, Thalhammer T (2013) Tumor-specific expression of organic anion-transporting polypeptides: transporters as novel targets for cancer therapy. J Drug Deliv. doi: 10.1155/2013/863539
17. van de Steeg E, van Esch A, Wagenaar E, Kenworthy KE, Schinkel AH (2013) Influence of human OATP1B1, OATP1B3, and OATP1A2 on the pharmacokinetics of methotrexate and paclitaxel in humanized transgenic mice. Clin Cancer Res 19:821-832. doi: 10.1158/1078-0432.CCR-12-2080
18. Okabe M, Unno M, Harigae H, Kaku M, Okitsu Y, Sasaki T, Mizoi T, Shiiba K, Takanaga H, Terasaki T, Matsuno S, Sasaki I, Ito S, Abe T (2005) Characterization of the organic cation transporter SLC22A16: a doxorubicin importer. Biochem Biophys Res Commun 333:754-762
19. González-Neira A (2012) Pharmacogenetics of chemotherapy efficacy in breast cancer. Pharmacogenomics 13:677-690. doi: 10.2217/pgs.12.44
20. McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, Clark GM (2006) REporting recommendations for tumor MARKer prognostic studies (REMARK). Breast Cancer Res Treat 100:229-235
21. Von Minckwitz G, Loibl S, Untch M (2012) What is the current standard of care for anti-HER2 neoadjuvant therapy in breast cancer? Oncology (Williston Park) 26:20-26
22. Elston CW, Ellis IO (1991) Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology 19:403-410
23. Miki Y, Suzuki T, Kitada K, Yabuki N, Shibuya R, Moriya T, Ishida T, Ohuchi N, Blumberg B, Sasano H (2006) Expression of the steroid and xenobiotic receptor and its possible target gene, organic anion transporting polypeptide-A, in human breast carcinoma. Cancer Res 66:535-542
24. Meyer zu Schwabedissen HE, Tirona RG, Yip CS, Ho RH, Kim RB (2008) Interplay between the nuclear receptor pregnane X receptor and the uptake transporter organic anion transporter polypeptide 1A2 selectively enhances estrogen effects in breast cancer. Cancer Res 68:9338-9347. doi: 10.1158/0008-5472.CAN-08-0265
25. Banerjee N, Allen C, Bendayan R (2012) Differential role of organic anion-transporting polypeptides in estrone-3-sulphate uptake by breast epithelial cells and breast cancer cells. J Pharmacol Exp Ther 342:510-519. doi: 10.1124/jpet.112.192344
26. Konig J, Seithel A, Gradhand U, Fromm MF (2006) Pharmacogenomics of human OATP transporters. Nauyn Schmiedebergs Arch Pharmacol 372:432-443
27. Zhang F, Yang Y, Smith I, Kau S-W, McConathy JM, Esteva FJ, Kuerer HM, Symmans WF, Buzdar AU, Hortobagyi GN, Pusztai L (2003) Correlation between HER-2 expression and response to neoadjuvant chemotherapy with 5-fluorouracil, doxorubicin, and cyclophosphamide in patients with breast carcinoma. Cancer 97:1758-1765
28. Learn PA, Yeh IT, McNutt M, Chisholm GB, Pollock BH, Rousseau DL Jr, Sharkey FE, Cruz AB, Kahlenberg MS (2005) HER-2/neu expression as a predictor of response to neoadjuvant docetaxel in patients with operable breast carcinoma. Cancer 103:2252-2260